Professional Documents
Culture Documents
6b.NEYRIKO Katexolamines.2013
6b.NEYRIKO Katexolamines.2013
6.
, ,
, ,
262
(DA), (NE)
.
( )
.
, ( )
( ).
.
, nitrogen ohne
radical (. ).
- 1884
. Schfer
, Oliver
,
, .
.
.
. ,
: ,
,
.
:
~80%
() ~20%
()
,
.
, -- (fright-fight-flight),
.40
, ,
.
,
263
264
4-[1--2()]-1,2-, , .
;
.
John Jacob Abel, ,
University of Michigan Ann Arbor Johns Hopkins Medical School
Baltimore, , .
,
,
, ,
. C17H15NO4.
Jokichi Takamine,
Parke Davis Company (Detroit, Michingan)
Abel 1899 1900. Abel
, Takamine,
,
, ,
Adrenalin ( e).
Takamine ,
. O T.B. Aldrich, Parke Davis
Company, Takamine C9H13NO3.
Jokichi Takamine
(1854-1922)
: ,
Journal of Biological Chemistry.
,
, Abel 10 C 10H13NO3.
, 9 .
.
Dakin Stolz
1904/5.
: - 1904
1904, Friedrich
Stolz (Farbwerke Hochst) Henry Drysdale Dakin (University of Leeds),
.
Friedrich Stolz
(1860 -1936)
265
266
: ,
acceleransstoff.
.
,
,
.
1936
. ,
,
, .
1910, Henry Dale
,
Otto Loewi (1873 1961)
,
Nobel 1936
. ,
. ,
,
, 1940.
- fight or flight
267
268
),
, . ,
, ,
( ).
,
,
, ,
-,
, o .
. 50
.
,
.
Parkinson, L-DOPA
.
DA 1939
1939,
Peter Holtz (19021970)
dopa decarboxylase,
CO2 L-Dopa.
Peter Holtz
(19021970)
6.24
Holtz Blaschko .
. 1946, Ulf von Euler
: ,
Cannon,
: .
Raymond Alquist
(1914 - 1983)
,
. , ,
( 5 10-5)
, .
,
, .
(<2%).
3,4- (DOPA: DihydrOxyPhenylAlanine) -
. 1964
4 60 kDa.
, .
, ,
.
,
--, --p- (),
269
270
1. :
,
.
--p- ()
DOPA (-),
DOPA-,
5- ( , .
6). ,
6,
.
DOPA ,
--dopa- (carbidopa). carbidopa
Parkinson L-DOPA, Sinemet.
, , , , L-DOPA,
, DA,
. carbidopa,
, DOPA- ,
L-DOPA .
1
.
.
: ,
--dopa-
(carbidopa)
,
.
.
6.25 .
+ DA,
+, .
+ .
,
, ,
(vesicular monoamine transporter, VMAT).
, , Ca2+
, . ,
, :
.
H Reserpine 1952 Rauwolfia serpentina
(Indian snakeroot), Sarpagandha
, .
.
Robert Wallace Wilkins 1950.
1953 1954.
Reserpine ( ),
VMAT.
271
272
Reserpine ,
.
, ,
. ,
- .
290 kDa Cu2+, 4
.
. - , Cu2+
Cu2+.
(DDC) FLA 63,
Cu2+.
, Fusarium heterosporium,
.
.
,
.
, ,
, -.
- ,
30 kDa.
() -- (COMT). H ,
.
: ,
.
, .
,
.
( ) -
, .
s ,
, , , , .
, . (OCD).
-, (
), .
- ,
MAO-B Parkinson.
: -
: - - Parkinson
s ,
. ,
.
273
274
,
, .
.
, , , ,
. cheese effect
(.
, , ).
C, Axelrod 1957. ,
S - .
90%
10% COMT
6.26 . DA:
90% DA 10%
COMT. DOPAC, HVA 3-.
: ,
90% DA .
3,4- (DHPA), 3,4 (DOPAC) .
40% DOPAC
COMT. 60% (HVA). DOPAC
HVA .
, 10% DA,
COMT, DA 3- (3-),
HVA .
COMT
6.27 .
:
COMT. (DHPGA MHPGA)
DHPG MHPG DHMA VA.
, DA :
COMT,
275
276
6.27.
, (3,4
(DHPGA)
3--4-- (MHPG)) .
.
3--4- (MHPG), ,
(VMA),
.
COMT
, ,
.
,
,
.
Tolcapone COMT
Parkinson levodopa/carbidopa ,
aromatic L-amino acid decarboxylase (AADC).
. ,
,
, ,
(DA
NE uptake). ( 5-)
,
Na+ ,
Na+-K+-ATP ( Na+-K+).
. Na+
, DA . Cl-
, .
DA
12 , 60-85 kDa,
5-,
GABA.
, , ,
.
: ,
DA,
.
,
,
, .
,
,
.
1859
( Novocain).
1932,
,
.
1960, .
,
. crack
1980.
,
()
1960,
5-,
, DA.
5- ,
.
277
278
(10-100 g/gm),
(1000-3000 g/gm).
.
.
: ,
4:1.
, ,
.
6.28
.
(substantia nigra)
(ventral
tegmental area)
:
(caudate putamen)
.
(cortex)
( )
.
(locus ceruleus)
(,
, ).
(lateral tegmental
area)
.
:
(locus ceruleus)
(lateral ventral tegmental fields).
.
:
, ,
, .
.
.
,
279
280
.
: 1) , 2)
3) .
,
. ,
,
.
.
;
R. Nicoll et al,
( -
), ,
( -
). , -
,
,
.
. (
40.000
5000).
: (substantia
nigra) (ventral tegmental area).
(striatum)) .
(cortex) ( )
.
6.29 :
.
: ,
Ahlquist, 1948,
, .
( ) -,
(phentolamine)
.
: -
: -
1967, Lands - : 1
, 2
.
1974, Langer - : 1
2 , 1981, Starke
1 (prazosin) 2
(yohimbine).
, ,
1- (1, 1, 1D), 2 (2, 2B, 2C) - (1, 2, 3).
1 2,
(Langer, 1974),
(Starke, 1981), C (McGrath, 1982).
281
282
6
.
1A, 1 1D :
C (PLC)
(3).
1A ,
, Ca2+-
, ,
1, 3
.
.
- 1 . 1-
7 ,
G.
, , (
1 ).
90 1D, 42 1, 25 1.
C, .
1
(161 ).
. (25 )
,
( )
. -
: (-COO-)
: ,
1-, (
),
.
,
1, 1, 1D
.
1-, .
, ,
, ()
.
283
284
xymetazoline: 1-
Phenylephrine: 1-
1- doxazolin prazosin
.
2 .
.
. 2-
: ,
2 ,
,
,
.
2-
, . 1 -
1950. ,
2- , ,
, .
2- .
2- ,
().
Clonidine: 2-
285
286
, REM,
.
, 2010,
ADHD (Attention deficit
hyperactivity disorder) .
2-
(prefrontal
cortex PFC).
(yohimbine)
Pausinystalia yohimbe (Yohimbe), . 2-,
,
.
. ,
, ,
. ,
, .
2-
, 1-20% 55
.
4.19
Pausinystalia yohimbe,
2-,
,
, .
: ,
- 1, 2 3, Gs
, ,
cAMP. 1- 1/ ,
( ), 2/
.
287
288
(metoprolol) 1 blocker
, ,
.
Atenolol: 1-blocker
Metoprololl: 1-blocker
2 , ,
. -
.
(salmeterol) 2-
(chronic obstructive
pulmonary disease, COPD).
. GlaxoSmithKline
1980 1990 Serevent.
(salbutamol) 2-
. 2 1968 Ventolin.
.
( 20 min) .
: ,
Barnes PJ., Haddad EB. and Rousell J., Regulation of muscarinic M2 receptors, Life
Sci.,1997, 60(13-14), 1015-1021
Birdsall NJ. et al, Selective allosteric enhancement of the binding and actions of
acetylcholine and muscarinic receptor subtypes, Life Sci.,1997, 60(13-14), 10471052
Brann MR., et al, Studies of the pharmacology, localization, and stucture of muscarinic
acetylcholine receptors, Ann. N.Y. Acad. Sci., 1993, 707, 225-236
Brown DA. et al, Muscarinic mechanisms in nerve cells, Life Sci.,1997, 60(13-14), 11371140
Brown JH. et al, Pathways and roadblocks in muscarinic receptor-mediated growth
regulation, Life Sci.,1997, 60(13-14), 1077-1084
Eglen RM., Hegde SS. and Watson N., Muscarinic receptor subtypes and smooth muscle
function, Pharmacol. Rev., 1996, 48(4), 531-565
Eglen RM. and Watson N., Selective muscarinic receptor agonists and antagonists,
Pharmacol. Toxicol., 1996, 78(2), 59-68
Felder CC., Muscarinic acetylcholine receptors: signal transduction trough multiple
effectors, FASEB J., 1995, 9(8), 619-625
Fisher A. et al, M1 agonists for the treatment of Alzheimers disease. Novel properties and
clinical update, Ann. N.Y. Academ. Sci., 1996, 777, 189-196
Jerusalinsky D. and Harvey A.L., Toxins from mamba venoms: small proteins with
selectivities for different subtypes of muscarinic acetylcholine receptors, Trends
Pharmacol. Sci., 1994, 15, 424-430
Hosey MM. et al, The role of G protein coupled receptor kinases in the regulation of
muscarinic cholinergic receptors, Prog. Brain Res., 1996, 109, 169-179
Klein J., Lindmar R. and Loffelholz K., Muscarinic activation of phosphatidyllcholine
hydrolysis, Prog. Brain Res., 1996, 109, 201-208
Lester HA., Activation of ion channels by acetylcholine: two contrasting transduction
pathways, Harvey Lect., 1995, 91, 79-98
Levey AI., Muscarinic acetylcholine receptor expression in memory circuits: implications
for treatment of Alzheimer disease, Proc. Natl. Acad. Sci. (USA), 1996, 93(24),
13541-13546
Loffelholz K., Muscarinic receptors and cell signalling, Prog. Brain Res., 1996, 109, 191194
Marchi M. et al, Presynaptic interactions between acetylcholine and glycine in the human
brain, Prog. Brain Res., 1996, 109, 225-229
Nahorski SR., Tobin AB. and Willars GB., Muscarinic M3 receptor coupling and
regulation, Life Sci.,1997, 60(13-14), 1039-1045
Nathanson NM., Regulation of muscarinic acetylcholine receptor expression and function,
Prog. Brain Res., 1996, 109, 165-168
Reever CM., Ferrari-DiLeo G. and Flynn DD., The M5 (m5) receptor subtype? fact or
fiction? Life Sci.,1997, 60(13-14), 1105-1112
Russell RW., Continuing the search for cholinergic factors in cognitive dysfunction, Life
Sci.,1996, 58(22), 1965-1970
Segal M. and Auerbach JM., Muscarinic receptors involved in hippocampal plasticity, Life
Sci.,1997, 60(13-14), 1085-1091
Tucek S. and Proska J., Allosteric modulation of muscarinic acetylcholine receptors,
Trends Pharmacol. Sci., 1995, 16(6), 205-212
Wess J., Molecular biology of muscarinic acetylcholine receptors, Crit. Rev. Neurobiol.,
1996, 10(1) 69-99
289
290
Wess J. et al, Structural basis of receptor/G protein coupling selectivity studied with
muscarinic receptors as model systems, Life Sci.,1997, 60(13-14), 1007-1014
Wess J. et al, Molecular aspects of muscarinic receptor assembly and function, Prog. Brain
Res., 1996, 109, 153-162
Albuquerque EX., et al, Nicotinic acetylcholine receptors on hippocampal neurons:
distribution on the neuronal surface and modulation of receptor activity, J. Recept.
Signal Transduct. Res., 1997, 17(1-3), 243-266
Arias HR., Topology of ligand binding sites on the nicotinic acetylcholine receptor, Brain
Res. Rev., 1997, 25(2), 133-191
Barrantes FJ., The acetylcholine receptor ligand-gated channel as a molecular target of
disease and therapeutic agents, Neurochem. Res., 1997, 22(4), 391-400
Birtwistle J. and Hall K., Does nicotine have beneficial effects in the treatment of certain
diseases? Br. J. Nurs., 1996, 5(19), 1195-1202
Boyd RT., The molecular biology of neuronal nicotinic acetylcholine receptors, Crit. Rev.
Toxicol., 1997, 27(3), 299-318
Changeux JP. et al, Nicotinic receptors and brain plasticity, Cold Spring Harb. Symp.
Quant. Biol., 1996, 61, 343-362
Clarke PB., Nicotinic receptors in mammalian brain: localization and relation to
cholinergic innervation, Prog. Brain Res., 1993, 98, 77-83
Colquhoun LM. and Patrick JW., Pharmacology of neuronal nicotinic acetylcholine
receptor subtypes, Adv. Pharmacol., 1997, 39, 191-220
Dani JA. and Heinemann S., Molecular and cellular aspects of nicotine abuse, Neuron,
1996, 16(5), 905-908
Froehner SC., Regulation of ion channel distribution at synapses, Ann. Rev. Neurosci.,
1993, 16, 347-368
Galzi JL. and Changeux JP., Neuronal nicotinic receptors: molecular organization and
regulations, Neuropharmacology, 1995, 34(6), 563-582
Gillin JC. et al, Cholinergic receptor subtypes and REM sleep in animals and normal
controls, Prog. Brain Res., 1993, 98, 379-387
Gotti C., Fornasari D. and Clementi F., Human neuronal nicotinic receptors, Prog.
Neurobiol., 1997, 53(2), 199-237
Hucho F., Tsetlin VI. and Machold J., The emerging three-dimensional structure of a
receptor. The nicotinic acetylcholine receptor, Eur. J. Biochem., 1996, 239(3), 539557
Imoto K., Ion channels: molecular basis of ion selectivity, FEBS Lett., 1993, 325(1-2),
100-103
Karlin A. and Akabas MH., Toward a structural basis for the function of nicotinic
acetylcholine receptors and their cousins, Neuron, 1995, 15(6), 1231-1244
Lindstrom J., Nicotinic acetylcholine receptors in health and disease, Mol. Neurobiol.,
1997, 15(2), 193-222
Lindstrom J. et al, Structure and function of neuronal nicotinic acetylcholine receptors,
Prog. Brain Res., 1996, 109, 125-137
Lena C. and Changeux JP., Allosteric modulations of the nicotinic acetylcholine receptor,
Trends Neurosci., 1993, 16(5), 181-186
Maelicke A., Nicotinic receptors of the vertebrate CNS: introductory remarks, Prog. Brain
Res., 1996, 109, 107-110
: ,
McGehee DS. and Role LW., Physiological diversity of nicotinic acetylcholine receptors
expressed by vertebrate neurons, Ann. Rev. Physiol., 1995, 57, 521-546
Newhouse PA., Potter A. and Levin ED., Nicotinic system involvement in Alzheimers
and Parkinsons diseases. Implications for therapeutics, Drugs Aging, 1997, 11(3),
206-228
Ortells MO. and Lunt GG., Evolutionary history of the ligand-gated ion-channel
superfamily of receptors, Trends Neurosci.,1995, 18(3), 121-127
Role LW. and Berg DK., Nicotinic receptors in the development and modulation of CNS
synapses, Neuron, 1996, 16(6), 1077-1085
Sargent PB., The diversity of neuronal nicotinic acetylcholine receptors, Ann. Rev.
Neurosci., 1993, 16, 403-443
Swope SL., Qu Z. and Huganir RL, Phosphorylation of the nicotinic acetylcholine receptor
by protein tyrosine kinases, Ann. N.Y. Acad. Sci., 1995, 757, 197-214
Vidal C., Nicotinic receptors in the brain. Molecular biology, function and therapeutics,
Mol. Chem. Neuropathol., 1996, 28(1-3), 3-11
Wonnacott S., Presynaptic nicotinic ACh receptors, Trends Neurosci., 1997, 20(2), 92-98
ifa E. and Fillion G., 5-hydroxytryptamine receptors, Pharmacol. Rev., 1992, 44, 401458.
Baxter G. et al, 5-HT2 receptor subtypes: a family re-united? TiPS, 1995,16, 105-109
Blier P., Bergeron R. and de Montigny C., Selective activation of postsynaptic 5-HT1A
receptors induces rapid antidepressant response, Neuropsychopharmacology, 1997,
16(5), 333-338
Boess FJ, and Martin IL., Molecular biology of 5-HT receptors, Neuropharmacology,
1994, 33, 275-317
Boess FJ. et al, Ultrastructure of the 5-hydroxytryptamine3 receptor, J. Neurochem., 1995,
64, 1401-1405
Buhot M.C, Serotonin receptors in cognitive behaviors, Curr. Opin. Neurobiol., 1997, 7(2),
243-254
Delgado PL., and Moreno FA., Hallucinogens, serotonin and obsessive-compulsive
disorder, J. Psychoactive Drugs, 1998, 30, 359-366
Engen R. et al, Central 5-HT4 receptors, TiPS, 1995,16, 391-397
Fanburg B.L. and Lee S.L., A new role for an old molecule: serotonin as a mitogen, Am. J.
Physiol., 1997, 272(5 Pt1): L795-L806
Fozard JR., and Kalkman HO., 5-Hydroxytryptamine and the initiation of migraine: new
perspectives, Naunyn-Schmiedebergs Arch. Pharmacol.,1994, 350, 225-9
Gilman P.K., The serotonin syndrome and its treatment, J. Psychopharmacol., 1999, 13,
100-9
Gthert M., et al, Genetic variation in human 5-HT receptors: potential pathogenetic and
pharmacological role, Ann. N.Y. Acad. Sci., 1998, 861, 26-30
Grant K.A., The role of 5-HT3 receptors in drug dependence, Drug and Alcool
Metabol.,1995, 38, 155-171
Hagan RM., Kilpatrick GJ., and Tyers MB., Interactions between 5-HT3 receptors and
cerebral dopamine function: implications for the treatment of schizophrenia and
psychoactive substance abuse, Psychopharmacology, 1993, 112, S68-75
Hartig P. et al, Alignment of receptor nomenclature with the human genome classification
of 5-HT1B and 5-HT1D receptor subtypes, TiPS, 1996, 17, 103-105
291
292
Hindle AT., Recent developments in the physiology and pharmacology of 5hydroxytryptamine, Br. J. Anaesth., 1994, 73, 395-407
oyer D. et al, International union of pharmacology classification of receptors for 5hydroxytryptamine (serotonin), Pharmacol. Rev., 1994, 46, 157-203
Hoyer D, et al, 5-Ht receptor classification and nomenclature: towards a harmonization
with the human genome, Neuropharmacology, 1997, 36(4-5), 419-428
Jackson . and Yakel J., The 5-HT3 receptor channel, Annu. Rev. Physiol., 1995, 57, 44768
Johnson K.W., et al, Serotonin in migraine: theories, animal models and emerging
therapies, Prog. Drug Res., 1998, 51, 219-44
Jolas T. et al, Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects 5-HT1A
receptor agonists and in their inhibitory effects on the firing of serotonergic neurons
in the rat? J. Pharmacol. Exper. Ther., 1995, 272, 920-929
Kirk E.E. et al, Serotonergic receptors as targets for pharmacology, J. Neurosci. Nurs.,
1997, 29(3), 191-197
Kroeze W.K, and Roth B.L., The molecular biology of serotonin receptors: therapeutic
implications for the interface of mood and psychosis, Biol. Psychiatry, 1998, 44,
1128-42
Martin GR, and Humphrey PP., Receptors for 5-Hydroxytryptamine: current perspectives
on classification and nomenclature, Neuropharmacology, 1994, 33, 261-73
Martin GR., et al, The structure and signaling properties of 5-HT receptors: an endless
diversity? TiPS, 1998, 19, 2-4
Morin L.P., Serotonin and the regulation of mammalian circadian rhythmicity, Ann. Med.,
1999, 31, 12-33
Olmo E. Et al, Ontogenetic development of 5-HT1D receptors in human brain: an
autoradiographic study, Eur. J. Neurosci.,1996, 8, 53-60
Parker R. et al, Allosteric modulation of 5-HT3 receptors: focus on alcohols and
anaesthetic agents, TiPS, 1996, 17, 95-99
Pauwels PJ., 5-HT1B/1D receptor antagonists, Gen. Pharmacol., 1997, 29(3), 293-303
Peroutka SJ, and Howell TA., The molecular of G protein-coupled receptors: focus on 5Hydroxytryptamine receptors, Neuropharmacology,1994, 33, 319-24
Roila F. and Del Favero A., Antiemetics revisited, Cuur. Opin. Oncol., 1997, 9(4), 321326
Seguin L. et al, The endogenous cerebral tetrapeptide 5-HT-moduline reduces in vivo the
functional activity of central 5-HT1B receptors in the rat, Neurosci. Res., 1997, 27,
277-280
Uphouse L., Multiple serotonin receptors: too many, not enough, or just the right number?
Neurosci. Biobehav. Rev., 1997, 21, 679-698
Van den Wyngaert I., et al, Cloning and expression of a human serotonin 5-HT4 receptor
cDNA, J. Neurochem., 1997, 69(5), 1810-1819
Whitaker-Azmitia PM., et al, Serotonin as a developmental signal, Behav. Brain Res.,
1996, 73, 19-29
Arnsten AF., Catecholamine regulation of the prefrontal cortex, J. Psychopharmacol.,
1997, 11, 151-162
Bremner JD., et al, Noradrenergic mechanisms in stress and anxiety: II. Clinical studies,
Synapse, 1996, 23, 39-51
Bylund DB., Pharmacological characteristics of alpha2-adrenergic receptor subtypes, ANN.
N.Y. Acad. Sci., 1995, 763, 1-7
: ,
293
294
: ,
Strosberg AD., Function and regulation of the beta3-adrenoceptor, Trends Pharmacol. Sci.,
1996, 17, 373-381
Strosberg AD., Structural and functional diversity of beta-adrenergic receptors, Ann. N.Y.
Acad. Sci., 1995, 757, 253-260
Strosberg AD., Structure and function of the beta3-adrenergicreceptor, Annu. Rev.
Pharmacol. Toxicol., 1997, 37, 421-450
Strosberg AD., Structure, function, and regulation of the three beta-adrenergic receptors,
Obes. Res., 1995, 3 (Suppl4), 501S-505S
Tobin AB., Phosphorylation of phospholipase C-coupled receptors, Pharmacol. Ther.,
1997, 75, 135-151
295
296